Thymosin Alpha-1 Safety in Young Adults (Ages 18 to 29): What the Evidence Actually Shows
HealthRX.com
Thymosin alpha-1 safety in healthy young adults is not established
Key numbers
- 1.6 mgDose strength of the finished Zadaxin injection covered by the Italian label, sold outside the United StatesSource: fda.gov, as cited Nov 7, 2026
- RR 0.72Serious adverse events versus comparison treatments in hepatitis B trials; low certainty; 5 trials, 1,056 peopleSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 45.8%HBeAg loss at 72 weeks with thymosin alpha-1 plus interferon in a double-blind trial of 98 adults with hepatitis BSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- Approval status / Not FDA-approved; authorized in some countries, including Italy, India and Hong Kong [2]
- Age in the approvals / India's hepatitis B approval covers adults 18 and older; Italy's covers immunocompromised people receiving influenza vaccination [2]
- Adverse events / May have caused fewer serious events than comparison treatments (RR 0.72, 95% CI 0.53 to 0.99; low certainty) [1]
- Label cautions / Pregnancy, breastfeeding, allergy, autoimmune disease, other immune-modulating drugs [2]
- Half-life / About 1.8 to 2.6 hours after subcutaneous injection [2]
- Compounding / In no category for state-licensed pharmacies; on the outsourcing-facility list it is category 3, nominated without adequate support [3][4]
- Sport / Not named on WADA's 2026 Prohibited List [5]
Who was actually studied
Thymosin alpha-1 (thymalfasin) is an immune modulator that augments T-cell function, given by subcutaneous injection [6][2]. The main comparative safety evidence comes from adults with chronic hepatitis B [1]. The 2026 Cochrane review pooled 10 randomized trials with 1,349 adults, published between 1991 and 2018 and run in Bangladesh, China, Italy, Korea, Singapore and Taiwan [1]. Its eligibility criteria covered people with chronic hepatitis B of any age, sex or ethnicity [1].
On outcomes, the reviewers found possible lower all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty, little to no effect on quality of life or liver histology, and said they were not sure the drug helps [1]. Results in individual trials have been mixed: in a double-blind trial of 98 adults, HBeAg loss at 72 weeks was 45.8% with thymosin alpha-1 plus interferon versus 28.0% with interferon plus placebo, a difference of 17.8% (95% CI -1.2 to 35.3) that was not statistically significant (P=0.067) [7].
India's authorization covers adults 18 or older with chronic hepatitis B, compensated liver disease and virus replication [2]. Italy's authorization is an adjuvant to influenza vaccination in immunocompromised people [2]. The approvals FDA describes for India and Italy do not cover a healthy 22-year-old taking it for general immune support.
What the label says to watch for
The Italian Zadaxin label covers the finished 1.6 mg injection sold outside the United States [2]. It says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution with allergies, autoimmune disease and other immune-modulating drugs [2].
Questions worth asking
Adverse events in the hepatitis B trials
Cochrane found that thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (RR 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (RR 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [1]. The comparisons were against placebo, no treatment or the same co-treatment, in people with liver disease.
FDA searched its adverse-event database on April 22, 2024 and found zero reports for the drug [2]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and over 17 million doses of Zadaxin given after marketing, with adverse experiences described as infrequent and mild; this is company-linked data [2].
The compounded product is a separate safety question
A compounded product is not FDA-approved [8]. FDA describes safety concerns about compounded thymosin alpha-1 [9]. Thymosin alpha-1 appears in none of the three categories on FDA's list for state-licensed pharmacies, and on the outsourcing-facility list it sits in category 3, nominated without adequate support [3][4]. It had been in category 2 for significant safety risks and moved to the nominated-but-withdrawn table when the nominators withdrew; FDA's stated concerns remain posted: significant risk of immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information the agency considers inadequate to understand the extent of any safety issues [9]. In December 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on both the free base and the acetate [10], and the peptide is not one of the six in HHS's October 2026 draft enforcement-discretion policy [11].
Sport and drug testing
WADA does not name thymosin alpha-1 on its 2026 Prohibited List [5]. WADA does name thymosin-beta-4 and derivatives such as TB-500, which is a different peptide [5]. The catch-all S0 category covers substances with no approval from any governmental health authority, and this one is approved in some countries [5][2].
Limits of the evidence
The hepatitis B trials enrolled people with liver disease, so they say little about fertility, sperm parameters or pregnancy outcomes in healthy adults aged 18 to 29 [1]. On interactions, the Italian Zadaxin label cautions about use with other immune-modulating drugs [2].
Frequently asked questions
Is thymosin alpha-1 safe for a healthy 22-year-old?
Can it be used during pregnancy or breastfeeding?
What side effects showed up in trials?
Is thymosin alpha-1 banned in sport?
Is compounded thymosin alpha-1 the same as Zadaxin?
What dose has been used?
References
Show all 11 referencesHide references
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
- Compounding and the FDA: Questions and Answers | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.